ZY19489+ferroquine

Zydus Cadila

Product vision
  • Uncomplicated malaria treatment and resistance management
MoA
  • ZY19489 new class of inhibitors, no resistance detected in vitro, mechanism of action unknown
  • Ferroquine (FQ), a 4-aminoquinoline: inhibition of haem detoxification
Key features
  • ZY19489: No stable resistance detected in in vitro or clinical studies
  • FQ: long duration of plasma exposure, fully active against amodiaquine and piperaquine resistant strains
Challenges
  • ZY19489: Synthesis and cost of goods

Status
  • ZY19489 phase I Multiple Ascending Dose completed in 2022
  • FQ: Two phase II studies in combination with OZ439 were completed in 2020; Ferroquine discovered by CNRS Lille and transferred to Sanofi; rights transferred from Sanofi to MMV
Next milestone
  • Completion of combination toxicology study
  • Initiate phase IIb combination study
Previously
  • ZY19489 discovery partnership between MMV and AstraZeneca, Bangalore
  • ZY19489 name AZ13721412; full reference name is MMV674253
MMV Project Director
  • Dr Gonzalo Acuña